



The Nifty ended 1.02% up at 13,529.10. It opened on a positive note and continued moving higher towards finishing off with a bullish candle. Candle pattern suggests the stock may soon challenge resistance placed around 13,630 levels. Hence, buying on dips is advised. Immediate support is placed around 13,430. Intraday retracement towards 13,430 may again find buyers, which might be helpful in taking the benchmark index higher towards 13,630 levels.

On the Nifty hourly chart; a channel breakout while the ADX is sharply rising suggests the benchmark index may continue oscillating with positive bias. Higher resistances are placed around 13,630 and 13,670 levels.

Nifty patterns on multiple time frames suggest; the benchmark index ended the day on a bullish note. Candle pattern along with position of leading indicators pointing towards continuation of current uptrend.

Nifty Crucial Supports & Resistances-

Supports- 13430, 13250 Resistances- 13630, 13670

Open Positional Calls-

T+5 Positional Buy-

|Cash Segment| LUPIN @ 945-940, TGT- 1000, SL- 910

T+3 Positional Buy-

|Cash Segment| AURO PHARMA @ 910- 905, TGT- 955, SL- 880

T+7 Positional Buy-

|Cash Segment| ITC @ 204-202, TGT- 218, SL- 194

T+5 Positional Buy-

|Cash Segment| MC DOWELL-N @ 602- 600, TGT- 640, SL- 580

T+10 Positional Option Pair Strategy-

|Leg 1| Buy ITC 31 Dec 215-CE (1 Lot=3200) @ 3.10

|Leg 2| Sell ITC 31 Dec 220-CE (1 Lot=3200) @ 2.10

Trade ends if ITC-Cash closes below 197.00

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

Indian equity markets continued their record breaking run, registering yet another record high, buoyed by a strong global sentiment.

The NIFTY index ended 1% higher at 13,529. The broader markets represented by the NIFTY 500 Index ended 0.83% higher, ending at 11181. NIFTY Media was the top gainer, gaining by 3.77%, followed by NIFTY Bank which ended by 1.48% higher. NIFTY PSU Bank was the top loser, losing by 1.02%.

UPL was the top gainer, gaining by 4.19%, followed by Asian Paints and IOCL which gained by 3.42% & 3.19% respectively. Hindalco Industries was the top loser, losing by 1.91%, followed by Shree Cement and Ultratech Cement, which fell by 1.43% & 1.40% respectively.

The Advance: Decline ratio stood at 1110:786

Market Turnover (In Crore) 09-12-2020

Name	Last	Previous
NSE Cash	*NA	69376.10
NSE F&O	2616664.62	2280190.75
BSE Cash	5,068.18	4,048.33
BSE F&O	*NA	216.29

FII Derivatives Flow (In Crore) 08-12-2020*

Instrument	Purchase	Sale	Net
Index Future	3536.16	3860.26	324.1
Index Option	240287.77	240972.18	684.41
Stock Future	13574.08	13555.20	18.88
Stock Option	5706.63	5711.27	4.64

Institutional Flow (In Crore) 08-12-2020*

Institution	Purchase	Sale	Net
FII	8473.34	5563.74	2909.60
DII	8473.34	6553.31	2640.93

*Data not updated till 5:25PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
UPL	4.19	11.46	13836059	12445470
Asian Paints	3.42	8.91	2022370	2856803
IOCL	3.19	6.28	34467763	29472660
Kotak Bank	2.71	3.82	4370644	5179116
HDFC Bank	2.25	0.02	11034537	12651190

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Maruti Suzuki	0.69	6.98	822760	2053929
Wipro	1.15	0.17	18137688	9552840
Ultratech Cement	1.40	4.29	1625022	1399290
Shree Cement	1.43	0.87	67836	59346
Hindalco Industries	1.91	3.95	14737004	24318700

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	46103.50	494.99	1.09	3.33	8.23	20.71	13.87
Nifty	13529.10	136.15	1.02	3.17	8.57	19.96	13.33
BSE M Cap	17596.17	70.89	0.40	2.50	13.09	21.83	19.84
BSE S Cap	17577.45	85.84	0.49	2.62	14.85	22.90	32.36
Nifty MC 100	20563.45	124.25	0.61	2.81	14.51	25.00	22.93
BSE Auto	21022.97	6.34	0.03	2.09	15.53	17.67	19.28
BSE Capgoods	17770.13	81.08	0.46	2.87	18.55	30.21	6.01
BSE FMCG	12254.90	117.97	0.97	4.19	8.95	8.32	6.49
BSE Metal	10995.22	15.28	0.14	3.37	23.58	25.27	15.77
BSE Oil&Gas	14288.53	130.86	0.92	3.81	13.94	11.55	3.45
BSE Healthcare	21184.36	19.74	0.09	2.66	7.89	13.15	59.01
BSE Power	2061.06	5.22	0.25	0.78	13.63	23.03	10.13
BSE Realty	2279.92	31.19	1.39	3.69	25.61	37.14	6.18
BSE ConsDur	28154.37	58.05	0.21	2.22	9.11	21.57	12.67
BSE Bank	35038.23	506.97	1.47	4.11	10.88	38.64	1.89
BSE IT	22873.61	232.80	1.03	2.55	3.87	24.60	52.29

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.94	0.02	2.53	0.54	1.91	34.42	48.26
UK	0.28	0.02	7.39	22.03	25.81	16.46	63.83
Brazil	3.39	0.00	0.06	1.68	0.42	5.26	11.57
Japan	0.02	0.00	15.79	15.39	4.76	29.03	1200.00
Australia	1.03	0.00	0.20	4.38	33.29	14.91	10.95
India	5.83	0.02	0.38	0.21	0.75	2.60	12.47
Switzerland	0.52	0.01	0.96	1.17	17.20	17.73	12.05
Germany	0.60	0.01	1.65	15.03	17.29	29.22	94.46

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.57	0.04	0.06	0.32	0.79	0.04	3.43
USD Index	90.75	0.21	0.23	0.40	2.13	2.68	7.06
YUAN	6.53	0.00	0.01	0.45	1.47	4.59	7.74
GBP	1.35	0.01	0.73	0.66	2.18	3.47	2.33
EUR	1.21	0.00	0.15	0.06	2.62	2.70	9.56
YEN	104.10	0.06	0.06	0.31	1.23	2.00	4.28

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1121.00	41.00	3.53	7.43	7.13	13.50	27.72
Baltic Dirty	439.00	1.00	0.23	1.13	8.93	1.79	67.19
SG Dubai HY	0.25	0.30	600.00	38.89	50.00	167.57	13.64

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	30173.88	104.09	0.35	1.17	3.48	7.99	8.11
Nasdaq	12582.77	62.82	0.50	1.84	7.42	12.94	45.94
S&P 500	3702.25	10.29	0.28	1.09	4.27	8.92	18.06
FTSE100	6589.22	30.13	0.46	1.94	6.51	9.58	8.92
CAC40	5570.96	10.91	0.20	0.20	4.41	10.48	4.55
DAX	13407.58	128.09	0.96	0.70	2.37	1.28	2.30
Mexico IPC	43098.64	156.61	0.36	0.47	8.69	19.20	2.73
Brazil Bovespa	113793.1	203.30	0.18	2.15	9.93	12.34	2.54
Russian RTS	1379.18	14.74	1.08	3.29	11.57	14.82	5.31
Japan Nikkei	26817.94	350.86	1.33	0.06	7.96	16.44	14.46
Hang Seng	26502.84	198.28	0.75	0.11	1.87	8.31	0.03
Taiwan Index	14390.14	29.74	0.21	2.87	9.62	14.13	23.41
Shanghai Comp	3371.96	38.21	1.12	2.24	0.05	3.61	15.70
KOSPI	2755.47	54.54	2.02	2.97	12.60	15.98	31.93
Malaysia KLCI	1646.53	14.83	0.91	2.99	8.02	10.01	5.36
Jakarta Comp	5944.41	13.65	0.23	3.84	10.99	15.44	4.03
Philippine SE	7102.66	101.01	1.40	1.33	6.24	17.71	8.96
Thai Exch	1482.67	3.75	0.25	4.35	15.30	14.63	4.53

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	45.88	0.27	0.59	1.30	13.85	20.55	22.28
BRENT Crude	49.11	0.26	0.53	1.76	14.85	16.02	16.95
Natural Gas	2.48	0.09	3.54	10.65	17.17	26.09	7.31

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1858.52	12.14	0.65	1.48	0.25	4.54	27.14
Silver(\$/Ounce)	24.27	0.28	1.15	0.70	0.69	10.03	46.16
Aluminium	1970.00	25.28	1.27	4.13	4.45	12.34	11.16
Copper	7679.00	16.00	0.21	0.12	10.73	14.69	28.80
Zinc	2773.75	13.75	0.50	0.77	5.71	16.17	23.69
Lead	2090.25	27.75	1.35	0.77	14.52	11.45	11.49

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	119.20	0.05	0.04	0.08	8.81	8.06	13.40
Cotton	71.96	0.02	0.03	0.50	0.39	10.40	6.07
Sugar	14.52	0.13	0.90	0.55	2.42	14.60	3.05
Wheat	568.25	1.75	0.31	3.44	6.15	2.76	2.43
Soybean	1155.50	4.00	0.35	0.06	4.22	17.76	22.24

Maruti Suzuki launches online car financing platform 'Smart Finance'

Maruti Suzuki India launched its multi-financier, online car financing platform 'Smart Finance'. The company is initially launching the platform in 30 cities through its premium car retail chain Nexa, targeting salaried customers with plans to expand its mass market chain Arena and customer base by the fourth quarter of this fiscal. Through the platform, the company is seeking to address the concerns of potential customers related to car finance in the 'new normal' by offering a comprehensive finance solution online with a bouquet of financing options. Under the Smart Finance platform, currently hosted on the NEXA website, company have partnered with several popular financiers to provide custom curated personalised loan offers for our customers. This digital service offers easy financing options and is completely transparent at each stage of the loan process. The customer gets to customise the EMI by choosing the loan tenure and interest rate and select a preferred down payment scheme. The platform enables customers to compare multiple scenarios for car loan and offers from different financiers, and make an informed choice of loan partner and loan tenure. For this, Maruti Suzuki said it has currently partnered with eight financiers - HDFC Bank, Yes Bank, ICCI Bank, IndusInd Bank, Cholamandalam Finance, AU Small Finance Bank, Mahindra Finance and Kotak Mahindra Prime.

Cabinet approves laying submarine optical fibre to provide high-speed broadband to Lakshadweep

The Union Cabinet on Wednesday approved laying of an undersea optical fibre cable to 11 Lakshadweep Islands to provide high-speed broadband internet connectivity. This would be on the lines of the one recently laid to Andaman & Nicobar Islands. The cabinet also approved setting up of 1 crore data centres.

Zydus Cadila gets USFDA Fast Track Designation for Saroglitazar

Zydus Cadila has received Fast Track Designation from the US health regulator for its investigational drug candidate Saroglitazar Mg, indicated for the treatment of a liver disease - primary biliary cholangitis (PBC). Fast Track is a process of the USFDA to expedite the review of drugs to treat serious conditions and fill an unmet medical need. A drug that receives Fast Track Designation is eligible for accelerated approval and priority review, if the relevant criteria are met. The United States Food and Drug Administration (USFDA) has granted Fast Track Designation to Saroglitazar Mg for the treatment of patients with PBC. The awarding of Fast Track Designation to Saroglitazar, an investigational candidate for the treatment of PBC, is an important recognition by USFDA to address the serious condition and bridge an unmet medical need in the treatment of PBC patients. The company will continue to work closely with the USFDA for clinical development for Saroglitazar Mg for patients with PBC. PBC is a liver disease, caused due to the progressive destruction of the bile ducts in the liver, which leads to a reduction of bile flow - a condition referred to as cholestasis.

RBL Bank, ICICI Prudential join hands for bancassurance partnership

RBL Bank and ICICI Prudential Life Insurance have joined hands under a bancassurance partnership to sell insurance policies to the bank's customers. As many as 398 RBL Bank branches across 28 states will distribute ICICI Prudential Life's protection and savings products. The alliance will enable over 8.7 million customers of RBL Bank to access and seamlessly purchase customer-centric protection and long-term savings products of the insurance company. Under the partnership, RBL Bank will distribute ICICI Prudential Life's products through its network of 398 branches spread across 28 states besides its internet and mobile banking touch-points, that distinguish the bank's multi-channel distribution network. For ICICI Prudential Life, the partnership will deepen and further strengthen its multi-channel distribution network. This collaboration empowers our customers to choose from a comprehensive suite of products and plan for a financially secure future. With our strong distribution reach and digital platforms, RBL Bank will be able to offer these products instantly to all our customer segments.

Aurobindo Pharma gets USFDA approval for drug used to sedate patients

Aurobindo Pharma has received final approval from the US health regulator for generic of Precedex injection, used for sedation of patients. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9 per cent sodium chloride injection, 200 g/50 mL and 400 g/100 mL single dose flexible containers (bags). Aurobindo said the approved product is a therapeutic equivalent generic version of Hospira's Precedex in 0.9 per cent sodium chloride injection. The company expected product will be launched in January 2021. Aurobindo now has a total of 459 abbreviated new drug application (ANDA) approvals (431 final and 28 tentative) from USFDA.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Shahlon Silk Industries Ltd	Cash dividend of INR0.25 effective 10-12-2020
Rushil Decor Ltd	Cash dividend of INR0.50 effective 10-12-2020
VLS Finance Ltd	Corporate meeting effective 10-12-2020
First Custodian Fund India Ltd	Corporate meeting effective 10-12-2020
Godawari Power and Ispat Ltd	Corporate meeting effective 10-12-2020
Sakuma Exports Ltd	Corporate meeting effective 10-12-2020
Frontier Capital Ltd	Corporate meeting effective 10-12-2020
Pansari Developers Ltd	Corporate meeting effective 10-12-2020
Lancor Holdings Ltd	Corporate meeting effective 10-12-2020

Domestic Events

- No Events

Global Events

- The U.S. Inflation for November 2020.
- The U.S. Initial Jobless Claims for December 05, 2020.
- ECB Interest Rate Decision.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com

